Compare INGN & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGN | SABS |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.4M | 201.4M |
| IPO Year | 2013 | N/A |
| Metric | INGN | SABS |
|---|---|---|
| Price | $6.95 | $3.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $11.25 | $10.75 |
| AVG Volume (30 Days) | 286.0K | ★ 352.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,668,000.00 | N/A |
| Revenue This Year | $8.03 | N/A |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $5.34 | $1.54 |
| 52 Week High | $9.13 | $6.60 |
| Indicator | INGN | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 37.60 |
| Support Level | $6.59 | $3.43 |
| Resistance Level | $7.46 | $4.11 |
| Average True Range (ATR) | 0.36 | 0.20 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 53.07 | 5.22 |
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.